The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

被引:18
作者
Wo, Jennifer Y. [4 ]
Shipley, William U. [1 ]
Dahl, Douglas M. [2 ]
Coen, John J. [1 ]
Heney, Niall M. [2 ]
Kaufman, Donald S. [3 ]
Zietman, Anthony L. [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02114 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Harvard Radiat Oncol Program, Boston, MA 02114 USA
关键词
BCG; failure; selective bladder-preserving chemo-radiotherapy; non-muscle invasive bladder cancer; TRANSITIONAL-CELL CARCINOMA; INTRAVESICAL THERAPY; TRANSURETHRAL RESECTION; RADICAL CYSTECTOMY; MANAGEMENT; TRIAL; RISK; PRESERVATION;
D O I
10.1111/j.1464-410X.2008.08299.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To report our original experience in patients in whom bacille Calmette-Guerin (BCG) therapy has failed for T1 bladder cancer with subsequent progression to T2 disease treated with chemo-radiotherapy, as the management of recurrent high-grade T1 bladder cancer after failed BCG therapy is challenging, and radical cystectomy is the standard treatment because there are no well established second-line bladder-preserving therapies. PATIENTS AND METHODS From 1988 to 2002, 18 patients with T2 recurrence after failure of BCG therapy for T1 bladder cancer were treated with chemo-radiotherapy at the authors' institution. Patients received a visibly complete transurethral resection of the bladder tumour (TURBT) and concurrent chemo-radiotherapy with a mid-treatment evaluation after 40 Gy. Patients with less than a complete response had a prompt cystectomy; the others completed radiotherapy to 64-65 Gy. The primary treatment outcome was freedom from cystectomy due to recurrence not treatable by conservative measures; secondary outcomes included disease-specific (DSS) and overall survival (OS). RESULTS With a median follow-up of 7.0 years, only one patient had persistent tumour at re-staging TURBT and had an immediate cystectomy. Of the remaining 17 patients, 10 (59%) were free of any bladder recurrence. The actuarial 7-year DSS and OS were 70% and 58%, respectively. At 7 years, 54% of patients were alive with intact bladders and free of invasive recurrence. CONCLUSIONS In this study we specifically evaluated patients with apparently small muscle-invasive recurrences after BCG treatment for T1 bladder cancer. Selective bladder preservation with chemo-radiotherapy is possible, with low morbidity and a high chance of long-term bladder control. If successful in treating T2 recurrences after BCG therapy, it now seems timely to critically evaluate chemo-radiotherapy as an alternative to immediate cystectomy in the management of patients with T1 recurrences after BCG.
引用
收藏
页码:179 / 183
页数:5
相关论文
共 16 条
[1]   Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy [J].
Bianco, FJ ;
Justa, D ;
Grignon, DJ ;
Sakr, WA ;
Pontes, JE ;
Wood, DP .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) :290-294
[2]   A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder [J].
Harland, S. J. ;
Kynaston, H. ;
Grigor, K. ;
Wallace, D. M. ;
Beacock, C. ;
Kockelbergh, R. ;
Clawson, S. ;
Barlow, T. ;
Parmar, M. K. B. ;
Griffiths, G. O. .
JOURNAL OF UROLOGY, 2007, 178 (03) :807-813
[3]   Cystectomy for transitional cell carcinoma of the bladder: Results of a surgery only series in the neobladder era [J].
Hautmann, Richard E. ;
Gschwend, Juergen E. ;
de Petriconi, Robert C. ;
Kron, Martina ;
Volkmer, Bjoern G. .
JOURNAL OF UROLOGY, 2006, 176 (02) :486-491
[4]   SUPERFICIAL BLADDER-CANCER - PROGRESSION AND RECURRENCE [J].
HENEY, NM ;
AHMED, S ;
FLANAGAN, MJ ;
FRABLE, W ;
CORDER, MP ;
HAFERMANN, MD ;
HAWKINS, IR .
JOURNAL OF UROLOGY, 1983, 130 (06) :1083-1086
[5]   EXPERIENCE WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY OF SUPERFICIAL BLADDER-TUMORS [J].
HERR, HW ;
PINSKY, CM ;
WHITMORE, WF ;
SOGANI, PG ;
OETTGEN, HF ;
MELAMED, MR .
UROLOGY, 1985, 25 (02) :119-123
[6]   The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy [J].
Lambert, Erica H. ;
Pierorazio, Phillip M. ;
Olsson, Carl A. ;
Benson, Mitchell C. ;
McKiernan, James M. ;
Poon, Steven .
BJU INTERNATIONAL, 2007, 100 (01) :33-36
[7]   Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach [J].
Luciani, LG ;
Neulander, E ;
Murphy, WM ;
Wajsman, Z .
UROLOGY, 2001, 58 (03) :376-379
[8]   Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder [J].
Maffezzini, Massimo ;
Campodonico, Fabio ;
Canepa, Giorgio ;
Capponia, Giacomo ;
Fontana, Vincenzo .
EUROPEAN UROLOGY, 2007, 51 (04) :956-961
[9]   Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy [J].
McKiernan, James M. ;
Masson, Puneet ;
Murphy, Alana M. ;
Goetzl, Manlio ;
Olsson, Carl A. ;
Petrylak, Daniel P. ;
Desai, Manisha ;
Benson, Mitchell C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3075-3080
[10]   Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer [J].
O'Donnell, MA ;
Lilli, K ;
Leopold, C .
JOURNAL OF UROLOGY, 2004, 172 (03) :888-893